Moderna Inc MRNA shares are trading higher by 5% at $194.22 Wednesday morning amid continued vaccine optimism.
The company announced an agreement with Thermo Fisher Scientific for fill/finish manufacturing of Moderna's COVID-19 vaccine, and a new drug substance production agreement with Lonza.
Moderna is commercial-stage biotech that was founded in 2010. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.